Aequus Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
18
- Stock Symbol
-
AQS
- Investments
-
3
Aequus Pharmaceuticals General Information
Description
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Contact Information
Website
www.aequuspharma.caCorporate Office
- 200 Granville Street
- Suite 2820
- Vancouver, British Columbia V6C 1S4
- Canada
Corporate Office
- 200 Granville Street
- Suite 2820
- Vancouver, British Columbia V6C 1S4
- Canada
Aequus Pharmaceuticals Stock Performance
As of 25-Apr-2025, Aequus Pharmaceuticals’s current market cap is $478K with 133M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $478K | 133M | 164K | -$0.01 |
Aequus Pharmaceuticals Financials Summary
As of 30-Sep-2025, Aequus Pharmaceuticals has a trailing 12-month revenue of $656K.
|
In Thousands, USD |
TTM 30-Sep-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 5,463 | 5,510 | 4,950 | |
| Revenue | 656 | 426 | 189 | 1,059 |
| EBITDA | (159) | (1,310) | (1,989) | (2,219) |
| Net Income | (469) | (1,588) | (2,195) | (2,464) |
| Total Assets | 141 | 558 | 819 | 1,246 |
| Total Debt | 4,332 | 4,607 | 3,817 | 2,050 |
Aequus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aequus Pharmaceuticals Comparisons
Industry
Financing
Details
Aequus Pharmaceuticals Competitors (1)
One of Aequus Pharmaceuticals’s competitors is Perrigo Company, a Corporation company based in Dublin, Ireland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Perrigo Company | Corporation | Dublin, Ireland |
Aequus Pharmaceuticals Patents
Aequus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2017029567-A1 | Transdermal and/or topical delivery system comprising clobazam | Inactive | 17-Aug-2015 | ||
| CA-2995431-A1 | Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride | Inactive | 17-Aug-2015 | ||
| EP-3337480-A1 | Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride | Inactive | 17-Aug-2015 | ||
| EP-3337480-A4 | Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride | Inactive | 17-Aug-2015 | ||
| US-20180250281-A1 | Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride | Inactive | 17-Aug-2015 | A61K31/4415 |
Aequus Pharmaceuticals Signals
Aequus Pharmaceuticals Investments & Acquisitions (3)
Aequus Pharmaceuticals’s most recent deal was a Joint Venture with Joint Venture (Aequus Pharmaceuticals / Medicom). The deal was made on 22-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (Aequus Pharmaceuticals / Medicom) | 22-Sep-2020 | Joint Venture | Other Devices and Supplies | ||
| Cannabis-based Therapies (CannaRoyalty / Aequus Pharmaceuticals) | 11-Jan-2018 | Joint Venture | Biotechnology | ||
| TeOra Health | 28-Jul-2015 | Merger/Acquisition | Pharmaceuticals |
Aequus Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Aequus Pharmaceuticals FAQs
-
When was Aequus Pharmaceuticals founded?
Aequus Pharmaceuticals was founded in 2013.
-
Where is Aequus Pharmaceuticals headquartered?
Aequus Pharmaceuticals is headquartered in Vancouver, Canada.
-
What is the size of Aequus Pharmaceuticals?
Aequus Pharmaceuticals has 18 total employees.
-
What industry is Aequus Pharmaceuticals in?
Aequus Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Aequus Pharmaceuticals a private or public company?
Aequus Pharmaceuticals is a Public company.
-
What is Aequus Pharmaceuticals’s stock symbol?
The ticker symbol for Aequus Pharmaceuticals is AQS.
-
What is the current market cap of Aequus Pharmaceuticals?
The current market capitalization of Aequus Pharmaceuticals is $478K.
-
What is Aequus Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Aequus Pharmaceuticals is $656K.
-
Who are Aequus Pharmaceuticals’s competitors?
Perrigo Company is a competitor of Aequus Pharmaceuticals.
-
What is Aequus Pharmaceuticals’s annual earnings per share (EPS)?
Aequus Pharmaceuticals’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process